Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
CSLCSLLY +3.64%73 Revenue per Share is $4.14 as of Dec. 2025. GuruFocus rates CSLLY with a GF Score™ of 73/100 and a GF Value™ of $50.38 (Significantly Undervalued). The stock has 7 warning signs investors should review. Among 768 Biotechnology companies, CSL ranks better than 69.27% on this metric.
CSL's revenue per share for the
six
months ended in Dec. 2025 was $4.14.
CSL's revenue per share for the trailing twelve months (TTM) ended in Dec. 2025 was $4.14.
Warning Sign:
CSL Ltd revenue per share is in decline over the past 12 months.
During the past 12 months, the average Revenue Per Share Growth Rate of CSL was -45.20% per year.
During the past 3 years, the average Revenue Per Share Growth Rate was 15.30% per year.
During the past 5 years, the average Revenue Per Share Growth Rate was 12.60% per year.
During the past 10 years, the average Revenue Per Share Growth Rate was 12.40% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate.
The historical rank and industry rank for CSL's Revenue per Share or its related term are showing as below:
CSLLY'
s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 3.9 Med: 14.7 Max: 23.9
Current: 15.3
During the past 13 years, CSL's highest 3-Year average Revenue Per Share Growth Rate was 23.90% per year. The lowest was 3.90% per year. And the median was 14.70% per year.
CSLLY's 3-Year Revenue Growth Rate is ranked better than 69.27% of 768
companies
in the Biotechnology industry
Industry Median: 3.1
vs CSLLY: 15.30
CSL (OTCPK:CSLLY) Revenue per Share Explanation
In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.
Peter Lynch categorized companies according to their revenue growth:
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
CSL Revenue per Share Related Terms
CSL Revenue per Share Historical Data
* Premium members only.
The historical data trend for CSL's Revenue per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CSLLY vs VRTX, REGN, RVMD: Revenue per Share Comparison
For the Biotechnology subindustry, CSL's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CSL PS Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, CSL's PS Ratio distribution charts can be found below:
* The bar in red indicates where CSL's PS Ratio falls into.
Revenue per Share is the amount of Revenue per outstanding share of the company's stock.
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
CSL's Revenue Per Share for the fiscal year that ended in Jun. 2025 is calculated as
Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was $4.14
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CSL (CSLLY) has a Revenue per Share of $4.14 as of Dec. 2025. Revenue per share equals the per-share value of a company's sales. View historical data on CSL and its competitors. According to the industry distribution chart, CSL ranks #236 out of 768 companies in the Biotechnology industry, placing it in the top 30.7%.
Is CSL's Revenue per Share too high?
CSL's current Revenue per Share is $4.14. The Biotechnology industry median Revenue per Share is 3.10. CSL's value of $4.14 is 33.5% above this industry median. Based on the distribution chart, CSL ranks #236 out of 768 companies in the Biotechnology industry, which is above the industry midpoint. Overall, CSL has a GF Score™ of 73/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does CSL's Revenue per Share compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, CSL ranks #236 out of 768 companies for Revenue per Share. This puts CSL in the upper half of its industry. The industry median Revenue per Share is 3.10. CSL's value of $4.14 is 33.5% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Revenue per Share for a Biotechnology company?
The median Revenue per Share among Biotechnology companies is 3.10, based on 768 companies in the industry. Companies in the top quartile (top 25%) have a Revenue per Share significantly above this median, while those in the bottom quartile fall well below. However, Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. CSL's current Revenue per Share of $4.14 is 33.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Revenue per Share mean?
A high Revenue per Share can signal that a stock is expensive relative to its fundamentals. Revenue per share equals the per-share value of a company's sales. View historical data on CSL and its competitors. For the Biotechnology industry, the median Revenue per Share is 3.10 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CSL's current Revenue per Share is $4.14. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CSL stock overvalued right now?
Based on GuruFocus' analysis, CSL (CSLLY) is currently considered Significantly Undervalued. The stock's GF Value™ is $50.38, compared to a current price of $21.08 — trading 58.2% below its estimated fair value. The current Revenue per Share is $4.14 and 33.5% above the Biotechnology industry median of 3.10. CSL's overall GF Score™ is 73/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Revenue per Share calculated?
Revenue per Share is calculated from a company's financial statements. For CSL (CSLLY), the current Revenue per Share is $4.14 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is CSL (CSLLY) Overvalued in 2026?
Based on GuruFocus' analysis, CSL stock appears to be undervalued.
The current stock price of $21.08 is trading 58.2% below its estimated GF Value™ of $50.38.
GuruFocus considers CSL to be Significantly Undervalued.
Key valuation signals for CSLLY:
Revenue per Share: $4.14
GF Value™: $50.38 vs. price of $21.08 (58.2% below fair value)
Industry Position: 33.5% above the Biotechnology median (#236 of 768)
No single metric tells the full story. See the CSLLY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
CSL is one of the largest global biotech companies and has three main segments. CSL Behring either uses plasma-derived proteins or recombinants to treat conditions including immunodeficiencies, bleeding disorders, and neurological indications. CSL Seqirus is the world's second-largest influenza vaccination business and was acquired in fiscal 2016. CSL Vifor is an iron deficiency and nephrology business and was acquired in fiscal 2023. CSL has a strong R&D track record, and the product portfolio and pipeline include nonplasma products as the firm continues to broaden its scope. Originally formed in Australia as a government-owned entity, CSL now earns roughly half its revenue in North America and a quarter in Europe.
73GF Score
Get the complete analysis for CSLLY
Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CSLLY has been successfully added to your 
